Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Why Cassava Sciences Was Up 15% in May

TheMotleyFool

0 0

Shares of Cassava Sciences (NASDAQ: SAVA) rose 15% in May, according to data provided by S&P Global Market Intelligence. After a positive meeting with the Food and Drug Administration (FDA) in February, its treatment for Alzheimer's Disease (AD) got more good news in May: It received a $2.7 million grant from the National Institutes of Health (NIH).

The relationship isn't new. The biotech has been developing the drug for more than 10 years and the NIH has been providing funding since 2017.

Image source: Getty Images.

Source Fool.com

Like: 0

SAVA

Share